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Background
Clinical or subclinical primary hyperparathyroidism 
(PHPT) is one of the most common endocrine disorders in 
the world. Since the 1970s, when measuring serum calcium 
and parathormone became routine, we have observed 
an increasing number of patients with PHPT (1). In the 
United States, the prevalence has jumped from 0.08 to 
about 0.5 per 1,000, and in Europe the prevalence is about 
3 per 1,000 overall, particularly affecting individuals aged 
55–75 years (2,3). PHPT is characterized by excessive 
secretion of parathyroid hormone (PTH), usually by 
enlarged parathyroid glands. PHPT is most frequently 
caused by a single adenoma (89%); hyperplasia of all the 
parathyroid glands or double adenomas are less frequently 
observed (6% and 4% respectively); in extremely rare cases 
it is caused by carcinoma (4). Among the many symptoms of 
PHPT, the most common is recurring nephrolithiasis due 
to hypercalcemia and low serum phosphate, osteoporosis, 
fractures, profound weakness and the involvement of other 
organs, e.g., neuropsychiatric abnormalities, depression, 
gastrointestinal and cardiovascular symptoms—all of 
which reduce the quality of life (5). Increasingly, however, 
especially in developed countries, we observe patients with 
asymptomatic PHPT or nontypical syndromes (6).
Generally, parathyroidectomy is the treatment of 
choice in symptomatic patients, stabilizing the progression 
of complications caused by the destruction activity of 
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PTH. However, there are some controversies regarding 
the indications for parathyroidectomy in asymptomatic 
patients. Over the past two decades the criteria used to 
qualify asymptomatic patients for parathyroidectomies 
have been reevaluated. The latest criteria for surgery of 
the parathyroid glands include serum calcium more than 
1.0 mg/dL above the reference limit, creatinine clearance 
<60 cc/min, markedly reduced bone density at any site (a 
T-score <−2,5 or fragility fracture), and age less than 50 years (7). 
Some cases with secondary hyperparathyroidism (S-HPT) 
and tertiary hyperparathyroidism (T-HPT) are indicated for 
parathyroidectomy as well. 
S-HPT is usually caused by chronic renal failure. 
Chronic renal insufficiency results from phosphorus 
retention. A strict inverse balance exists between serum 
levels of phosphorus and calcium, so that phosphorus 
retention induces hypocalcemia, which stimulates PTH 
secretion and parathyroid enlargement. Other causes 
of S-HPT include vitamin D deficiency or intestinal 
malabsorption. T-HPT refers to the development of 
autonomous parathyroid hyperfunction, characterized 
by hypercalcemic hyperparathyroidism in patients with 
preexisting S-HPT. Bone pain, skeletal deformities (renal 
osteodystrophy), muscle weakness, growth retardation 
and extraskeletal calcifications are the main clinical 
manifestations of this disorder (5,8). 
Persistent or recurrent hyperparathyroidism is another 
indication for parathyroidectomy; it occurs in 5–10% of 
patients following primary parathyroidectomy. If the serum 
calcium level is elevated in the immediate postoperative 
period, persistent hyperparathyroidism is recognized. It 
is caused by a failure to localize the abnormal parathyroid 
gland, inadequate resection of unrecognized multi-gland 
disease, or the presence of metastatic parathyroid carcinoma. 
Familial hyperparathyroidism, especially multiple endocrine 
neoplasia type 1 (the MEN1 syndrome), usually predisposes 
the patient to persistent hyperparathyroidism. In cases when 
hyperparathyroidism reappears after a period exceeding 
6 months after surgery, recurrent hyperparathyroidism is 
recognized (9).
Since the first successful parathyroidectomy was 
performed in 1925 with bilateral neck exploration, it came 
to be viewed as the treatment of choice in PHPT (10). 
Parathyroid surgical techniques have evolved over the years 
from bilateral neck exploration, to minimally invasive single 
parathyroid gland exploration, to minimally invasive video-
assisted parathyroidectomy (11). 
Localization of the abnormal parathyroid gland before 
surgery is crucial for the operation to be effective. The 
main difficulty in locating the parathyroid glands is their 
unpredictable location resulting from migration in the 
embryonic period. In 80% of patients, the parathyroids are 
located on the posterior capsule of the thyroid, above and 
inferior to the crossing of the recurrent laryngeal nerve and 
inferior thyroid artery (11-13). In 15% they are located on 
the posterolateral surface of the superior thyroid gland. In 
5% of cases the parathyroids more posterior in the neck, 
in retropharyngeal or retroesophageal position. Symmetry 
is more often observed in the superior parathyroid glands; 
only 70% of the inferior glands are symmetric (14). About 
0.5–4% of all parathyroid glands are hidden in the thyroid. 
Anomalies in parathyroid numbers are observed in 3–6% of 
individuals (5,13,14). 
Many years ago, when parathyroid surgery was first 
developed, preoperative diagnoses of the parathyroid glands 
were not as important as the experience and skill of the 
surgeon performing the operation, particularly in cases of 
PHPT. Bilateral exploration of the neck was usually the 
main way to localize parathyroid pathologies. But increased 
incidences of reoperations of the parathyroid glands and the 
rapid development of minimally invasive methods led to the 
development of new localization techniques (15). Nowadays 
various noninvasive and invasive imaging studies are 
available. The noninvasive studies include ultrasound (US), 
computed tomography (CT), magnetic resonance (MR) 
and 99mTc-methoxyisobutylisonitrile (MIBI) scintigraphy 
combined with single-photon emission CT (SPECT/CT). 
Invasive studies, usually reserved for reoperative cases, 
include US or CT-guided fine-needle aspiration (FNA) 
with concomitant PTH assay, parathyroid angiography and 
selective venous sampling (SVS) for the PTH gradient (11). 
Among the latest technologies, the four-dimensional (4D)-
CT scan, positron emission tomography (PET)/CT and 
PET/MR are very promising, and are going to have surgical 
implications in the future. 
Neck US 
Ultrasonography was introduced in the late 1970s 
particularly for diagnosing PHPT. As a noninvasive, 
inexpensive method with no radiation or contrast, US is 
usually still the first method used before surgery to localize 
parathyroid abnormalities. Generally, a normal parathyroid 
gland cannot infallibly be visualized with US, but enlarged 
hypercellular adenomas have a distinct appearance 
that allows them to be detected. Typical US features of 
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parathyroid adenomas are homogeneous hypoechoicity, 
ovoid shape, hypervascularity in power Doppler imaging 
and, often, an extrathyroidal feeding vessel entering the 
parathyroid gland at one of the poles (16,17). US is most 
useful in identifying parathyroid adenomas that are close 
to the thyroid gland, but less useful in cases of abnormal 
tissue localized ectopically in the neck, behind the trachea/
esophagus, or in the mediastinum. The sensitivity and 
positive predictive value (PPV) of US for detecting enlarged 
parathyroid glands ranges from 51% to 96%, and the 
specificity is 71% (18-20). US is quick, noninvasive, safe 
and less expensive than other imaging methods. However, 
several factors decrease the sensitivity and PPV of US, for 
example concomitant thyroid nodules, multiple parathyroid 
adenomas or parathyroid hyperplasia (21,22). It is possible 
to use ultrasonography intraoperatively to more precisely 
locate parathyroid adenomas or for US-guided fine-
needle biopsy to measure the PTH level, which can help 
to differentiate an intrathyroid parathyroid adenoma from 
thyroid nodules (22). The disadvantages of this method 
include its low value in cases of non-anatomical localizations 
(substernal, retrotracheal or intramediastinal) of parathyroid 
glands and its inability to distinguishing parathyroid 
gland from lymph nodes (15,23). Another limitation of 
this technique is operator-dependent. According to many 
authors, USs performed by parathyroid surgeons have 
been shown to have a higher sensitivity than radiologist-
performed parathyroid ultrasonography (24-26).
CT, 4D-CT
Contrast-enhanced CT is a valuable radiological imaging 
tool for localizing parathyroid adenomas. The main 
advantage of this method is that scanning from the base of 
the skull to the mediastinum allows the detection of ectopic 
adenomas. The most difficult to find are small parathyroid 
adenomas, because lymph nodes or tortuous vessels may be 
mistaken for them. The reported sensitivity of CT ranges 
from 46% to 87% (19,27,28).
4D-CT is a novel method of multiphase CT imaging, 
characterized by rapid, easily reproducible high-resolution 
images of anatomic details, useful for surgical planning. 
The name comes from 3-dimensional (3D)-CT with 
the addition of a fourth dimension based on changes in 
contrast perfusion in the tissues over time, which helps 
identify adenomas more clearly than normal 3D-CT. 
Parathyroid adenomas have rapid uptake and early washout 
of intravenous contrast compared to the thyroid. Typically, 
the 4D-CT protocol for parathyroid adenoma localization 
includes a pre-contrast scan, an arterial phase scan 
(25–30 seconds after the contrast bolus), a venous phase 
scan (approximately 30 seconds after the arterial phase scan) 
and a delayed phase scan (about 30 seconds after the venous 
phase scan). The reported sensitivity of 4D-CT scans is as 
high as 88% (29). The main challenge in the interpretation 
of 4D-CT images is differentiating parathyroid adenomas 
from normal lymph nodes, thyroid nodules and vascular 
structures. Vu et al. showed that parathyroid adenomas 
had lower baseline density than thyroid tissue, a greater 
increase in density from baseline to the arterial phase than 
the thyroid gland, and much faster contrast washout in the 
venous and delayed phases than the thyroid (30). Careful 
observation during the early arterial phase allows vascular 
structures to be distinguished from parathyroid adenomas. 
The lymph nodes, in turn, show no enhancement in the 
arterial phase (31). Eichhorn-Wharry et al. showed that 4D-
CT is particularly successful in cases of mild hypercalcemia, 
elevated PTH and smaller adenomas (32).
Magnetic resonance
Another type of radiological imaging used to locate 
parathyroid adenomas is MR, which is especially useful 
for patients who require reoperation because of persistent 
or recurrent hyperparathyroidism. In MR imaging a 
typical parathyroid adenoma is an enhancing lesion with 
isointensity on T1-weighted images and increased signal 
intensity on T2-weighted images. However, on both T1- 
and T2-weighted images, parathyroid adenomas may appear 
isointense or enhanced (33). In the past, 1.5 Tesla and non-
dedicated protocols were followed, and the sensitivity of 
MR was reported as 43–71%, comparable to CT (34). As in 
CT scans, in MR imaging enlarged lymph nodes, thyroid 
nodules or tortuous vessels can cause false positives (35). 
The development of 3 Tesla MR and dedicated protocols for 
the neck improved the sensitivity of parathyroid adenoma 
detection. Argiro et al. compared the effectiveness of 99mTc-
MIBI and 3 Tesla MR imaging in parathyroid adenoma 
localization; they reported the sensitivity of 3 Tesla MR 
as 97.7%, the specificity as 97.5%, with PPV 93.7% and 
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negative predictive value (NPV) 99.2% (36). 
Nuclear medicine imaging
99mTc-MIBI scintigraphy
The most common nuclear medicine imaging technique for 
preoperative localization of parathyroid adenomas is 99mTc-
MIBI scintigraphy. This method based on the preferential 
uptake of sestamibi in mitochondria-rich parathyroid 
adenoma cells and no uptake in normal functioning 
parathyroid glands. Two different acquisition methods 
have been used: subtraction and dual-phase images. In the 
subtraction method, a radiotracer specific to thyroid, such 
as 99mTc-pertechnetate or 123iodium, is subtracted from a 
scan with 99mTc-MIBI to enhance parathyroid adenomas. 
Dual-phase imaging is based on early and delayed images 
following intravenous administration of 99mTc-MIBI 
(10–15 minutes vs. 2–3 hours). Parathyroid adenomas 
exhibit increased uptake and persistence of radiotracer 
activity, which is washed out of normal thyroid tissue (37). 
Unfortunately, in up to 30% of patients this characteristic 
washout is not seen (38). Three imaging methods have been 
used in parathyroid scintigraphy: 2-dimensional planar 
imaging, 3D SPECT and SPECT/CT combined with low-
dose CT (SPECT/CT). The hybrid SPECT/CT method 
has been shown to be superior to normal SPECT, dual-
phase planar and subtraction scintigraphy because of the 
combined functional and anatomical information. 
At present, 99mTc-MIBI SPECT/CT is the most 
frequently used nuclear imaging method (Figure 1). 
However, it gives false negatives in as many as 30% of 
cases (39). The sensitivity of 99mTc-MIBI SPECT/CT 
scintigraphy ranges from 61% to 79%, and the specificity 
is 71%. It is more reliable in identifying larger parathyroid 
adenomas (>1.8 cm) (40); the most frequent cause of false-
negative scintigraphy results are smaller parathyroid 
adenomas (41). The most difficult is to localize are small 
parathyroid adenomas (<1.4 mL), ectopic adenomas, 
adenomas in patients with coexistent multinodular goiter 
and in patients who have undergone primary neck surgery. 
Functional imaging with 99mTc-MIBI scintigraphy may 
give false positives, because some hyperplastic thyroid 
lesions have extended retention of 99mTc-MIBI. The most 
important factors influencing the PPV of scintigraphy are 
the presence of concomitant thyroid nodules and the size 
of the parathyroid adenoma. Each method has its strong 
and weak points, but the sensitivity of combined 9mTc-MIBI 
SPECT/CT scintigraphy is as high as 80% (42). 
99mTc-MIBI is also the only radiotracer used to localize 
parathyroid adenomas by intraoperative radioguidance. An 
intraoperative gamma-probe detector is most successful 
2–3 hours after intravenous tracer injection. Norman 
et al. carried out scintigraphy on the day of surgery, 
administering 740 MBq of 99mTc-MIBI intravenously. Dual-
phase scintigraphy was performed 20 minutes and 2 hours 
after the injection; after approximately 2.5–3 hours, gamma-
probe guided surgery began (43,44). Casara et al. performed 
99mTc-MIBI scintigraphy a few days before surgery; 
then low-dose 37 MBq 99mTc-MIBI was ok administered 
intravenously just before the start of the operation, and 
intraoperative PTH (IOPTH) monitoring was used to 
confirm complete removal of the parathyroid adenoma 
(45,46). Although 99mTc-sestamibi scans are now the most 
common nuclear medicine imaging technique used for 
preoperative localization in PHPT, a more sensitivity 
nuclear medicine imaging technique is needed.  
PET/CT and PET/MR
Hybrid PET and CT scanning is one of the most accurate 
imaging methods for diagnosis because of the fusion of 
anatomical data from CT and metabolic information from 
PET (Figure 2). PET/CT is used for diagnosis in oncology, 
cardiology and neurology. Replacing CT with MR, hybrid 
PET/MR imaging is usually better for diagnosing or 
Figure 1 Parathyroid adenoma under right lobe of thyroid—99mTc-
MIBI SPECT/CT. MIBI, methoxyisobutylisonitrile; SPECT, 
single-photon emission computed tomography; CT, computed 
tomography.
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assessing diseases that are better seen in MR imaging—
for example prostatic cancer. Many different radiotracers 
are used in PET imaging. To diagnose parathyroid 
adenomas, the most promising radiotracer appears to be 
18F-flurocholine (18FCH). Choline plays an essential role in 
the biosynthesis of the phospholipids of cell membranes. 
So far, 18FCH PET/CT has been used for the staging 
and restaging of patients with clear cell renal carcinoma 
and prostate cancer. The currently available data show an 
increased accumulation of choline in parathyroid adenomas 
as well as in hyperplastic parathyroid glands. Broos et al. 
showed that the highest sensitivity of 18FCH PET/CT 
was 97% (47). In a prospective dual-center study with 100 
patients with PHPT, Beheshti et al. compared the sensitivity 
18FCH PET/CT and 99mTc-MIBI scintigraphy. 18FCH PET/
CT imaging was performed 60 minutes after intravenous 
injection of 3.2 MBq of 18FCH per kg of body weight. The 
sensitivity of PET/CT was 93.7%, which was markedly 
greater than that of 99mTc-MIBI SPECT/CT, which showed 
a sensitivity of 60.8%. The specificity, PPV, NPV and 
overall accuracy of 18FCH PET/CT in the detection of 
parathyroid adenomas were 93.7%, 96.0%, 90.2%, 97.4% 
and 95.3% respectively (48). Huber et al. published the 
results of 26 patients with PHPT who underwent 18FCH 
PET/CT or PET/MR scanning. Adenomas were detected 
in 25 patients (96.2%), confirmed intraoperatively, and 
none of the patients needed revision surgery during the 
follow-up (49). In 2017, Kluijfhout et al. published the 
results of a prospective pilot study of 18FCH PET/MR 
imaging in ten patients with negative or inconclusive results 
of US and 99mTc-MIBI scintigraphy scans for parathyroid 
adenomas. After intravenous administration of 3 MBq/
kg of 18FCH, PET imaging was performed, as well as T1- 
and T2-weighted MR imaging before and after contrast 
enhancement. The authors showed 90% sensitivity and 
100% PPV for 18FCH PET/MR. The median adenoma 
SUVmax was 4.9, which was significantly higher than the 
thyroid SUVmax (2.7) (P=0.008) (50).
 
Conclusions
Parathyroid imaging should be considered only when 
a diagnosis of hyperparathyroidism and indications for 
surgery have been established and the patient has agreed 
to undergo surgery (11,37). Historically, four-gland 
parathyroid exploration during bilateral neck revision by an 
experienced surgeon was the standard of care. Nowadays 
surgeons are focused on smaller incisions and less soft-
tissue dissection, so minimally invasive parathyroidectomy 
(MIP) is performed in the majority of patients with 
hyperparathyroidism. MIP has changed surgeons' views 
on the necessity of preoperative parathyroid diagnoses, 
since it is possible only with a precise location established 
preoperatively. Moreover, precise preoperative localization 
is crucial for patients undergoing reoperation or in cases of 
persistent hyperparathyroidism (1,6,11,15,37).
There are two different algorithms for localizing 
parathyroid pathologies in first-time operations and 
in cases of recurrence or persistent disease (11). In a 
primary parathyroidectomy accurate localization allows 
surgeons to perform a minimally invasive procedure. 
When a biochemical diagnosis of hyperparathyroidism is 
confirmed in patients with or without symptoms, US and 
99mTc-sestamibi scans are usually performed; two positive 
and concordant examinations allow surgeons to fine-
tune parathyroid surgery. If one of the images is negative, 
focused exploration with IOPTH measurement or unilateral 
exploration for two parathyroid glands is recommended. If 
both the US and the 99mTc-sestamibi are negative, or when 
they are or discordant, bilateral exploration with IOPTH 
Figure 2 Parathyroid adenoma—18F-fluorocholine PET/CT. PET, positron emission tomography; CT, computed tomography.
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measurement is the standard protocol (51). 
Re-operation of the parathyroid glands is a surgical 
coup de maître requiring not only perfect localization, but 
also supporting documentation such as previous surgical 
and pathology reports. The localization study includes 
many tests, ranging from the noninvasive (US, 99mTc-
MIBI, CT, MR, PET/CT, PET/MR) to the invasive 
(SVS and FNA) (11,51). FNA parathyroid biopsy was 
first described in the 1980s (52,53). The main advantage 
of FNA biopsy is the high specificity in distinguishing 
parathyroid and non-parathyroid tissues. This test should 
not be used before primary operations, as it is an invasive 
method. Measuring the PTH levels of the aspirate is more 
sensitive than FNA cytology, which could be mistaken for 
follicular thyroid tissue (54). The development of the PTH 
radioimmunoassay led to SVS. The accuracy of this method 
is 83%, and the sensitivity with intact PTH assay (IPTH) is 
about 95% (21). SVS is reserved for parathyroid reoperation 
in case of negative, equivocal or conflicting noninvasive 
studies. Technically SVS is a very difficult examination, 
requiring an experienced interventional radiologist. 
Fine needle biopsy (FNB) is considered the first invasive 
procedure to try in cases where US and 99mTc-MIBI fail to 
provide the two concordant tests needed before parathyroid 
reoperation can commence. SVS should be considered 
only where CT, 4D-CT, MR, PET/CT or PET/MR are 
unavailable (11,37). The comparison of advantages and 
disadvantages of different parathyroids imaging techniques 
is shown in Table 1. 
Finally, the choice of parathyroid imaging method 
requires knowledge of the radiation dose given. Effective 
dose of 99mTc-MIBI SPECT is about 6 mSv when 
administered radioactivity is 740 MBq. If low dose CT 
is added to the SPECT effective dose increases to about 
8–9 mSv. Absorbed dose for thyroid is about 4 mGy. The 
correct choice of radiation dose is particularly important 
in patients where parathyroid gland disorders coexist with 
thyroid disease. The dose of the radiation dose given after 
4D-CT could block iodine uptake of the thyroid for many 
weeks (14,55).
To sum up, there is no perfect imaging method for the 
parathyroid gland, and selecting the best preoperative 
imaging to localize parathyroid glands is difficult. The 
sensitivities of imaging techniques vary significantly 
from institution to institution, depending on the levels 
of expertise and variations in the patient populations. 
Moreover, the results vary between high- and low-volume 
centers (41). Hyperparathyroidism is seldom a problem in 
the general population, with a prevalence of about 0.7%. 
There are usually few centers in any given country where 
high-volume surgeons perform these operations (42). 
That is why there is no single superior way to diagnose 
parathyroid pathology before surgery. High-definition US is 
still the main examination considered basic in preoperative 
localization imaging for PHPT. The use of more than 
one imaging method usually provides more accurate 
preoperative localization. Among the new techniques, the 
most promising seem to be 4D-CT and PET/CT or PET/
MR scanning, but neither of these is widely available in 
in low-volume centers. In the majority of centers, 99mTc-
Table 1 The comparison of advantages and disadvantages of different parathyroid imaging techniques 
Examinations Advantages Disadvantages
First-line
US Noninvasive, inexpensive, no radiation or 
contrast, easily accessible
Sensitivity, operator-dependent
99mTc-MIBI SPECT/CT Low-dose radiation Sensitivity, depend of size of parathyroid adenoma 
and coexistent multinodular goiter
Second-line
CT and 4D-CT Higher sensitivity, successful in cases of mild 
hypercalcemia and smaller adenomas
Higher dose of radiation
MR Higher sensitivity, especially useful for patients 
who require reoperation
Less availability
PET/CT and PET/MR Higher sensitivity, functional examination Less availability
US, ultrasound; MIBI, methoxyisobutylisonitrile; SPECT, single-photon emission computed tomography; CT, computed tomography; PET, 
positron emission tomography; MR, magnetic resonance.
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MIBI scans are the most frequently performed, although 
they have a low rate of sensitivity compared to SPECT/
CT (11,37,41). Possible imaging techniques and their 
implications for surgical treatment should be considered 
in the context of overall expenses: a higher initial imaging 
cost imaging may result in higher rates of intraoperative 
parathyroid localization, lowering the overall costs of 
parathyroid treatment. Finally, it should be mentioned 
that the choice of a given imaging method to much extent 
is determined by the availability of a given test in a local 
healthcare environment. Unfortunately, imaging techniques 
such as CT, 4D-CT, MR, PET/CT or PET/MR are still 
unavailable in many small centers all over the world.
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